Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.

[1]  V. Buckalew,et al.  Sodium, water, and congestive heart failure. , 1984, Annals of internal medicine.

[2]  J. Corbett,et al.  Central and regional hemodynamic effects and neurohumoral consequences of minoxidil in severe congestive heart failure and comparison to hydralazine and nitroprusside. , 1983, The American journal of cardiology.

[3]  D. Gillmer,et al.  Pulmonary oedema precipitated by nifedipine. , 1980, British medical journal.

[4]  N. Fineberg,et al.  Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans. , 1985, Hypertension.

[5]  M. Packer,et al.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.

[6]  N. Lasker,et al.  Mechanisms of hyponatremia in chronic congestive heart failure. , 1961, Annals of internal medicine.

[7]  E. Braunwald,et al.  Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. , 1981, The American journal of medicine.

[8]  S. Glantz.  Biostatistics: how to detect, correct and prevent errors in the medical literature. , 1980, Circulation.

[9]  W. Parmley,et al.  The role of vasodilator therapy in heart failure. , 1977, Progress in cardiovascular diseases.

[10]  R. Magorien,et al.  Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow. , 1984, American heart journal.

[11]  A. Ellrodt,et al.  Salutary hemodynamic and sustained clinical beneficial effects of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure. , 1985, American heart journal.

[12]  H. Schedl,et al.  AN EXPLANATION FOR ABNORMAL WATER RETENTION AND HYPOOSMOLALITY IN CONGESTIVE HEART FAILURE. , 1964, The American journal of medicine.

[13]  M. Thames,et al.  Stimulation of cardiac receptors with veratrum alkaloids inhibits ADH secretion. , 1980, The American journal of physiology.

[14]  L. E. Alves,et al.  Use of nifedipine in older patients and patients with congestive heart failure. , 1982, The American journal of medicine.

[15]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[16]  J. Ferlinz,et al.  Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure , 1983 .

[17]  P. Cannon.  The kidney in heart failure. , 1977, The New England journal of medicine.

[18]  J. Laragh,et al.  Evaluation of calcium-mediated vasoconstriction in chronic congestive heart failure. , 1983, The American journal of medicine.

[19]  M. Thames,et al.  Cardiopulmonary receptors with vagal afferents tonically inhibit ADH release in the dog. , 1979, The American journal of physiology.

[20]  D. Warltier,et al.  Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist. , 1981, The Journal of pharmacology and experimental therapeutics.

[21]  V. Campese,et al.  Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure. , 1984, Journal of the American College of Cardiology.

[22]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[23]  M. R. e Silva,et al.  The release of vasopressin in response to haemorrhage and its role in the mechanism of blood pressure regulation , 1969, The Journal of physiology.

[24]  G. Robertson,et al.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. , 1973, The Journal of clinical investigation.

[25]  D. Alling,et al.  Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. , 1985, The American journal of medicine.

[26]  M. Packer,et al.  Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure. , 1982, Progress in cardiovascular diseases.

[27]  C. McKay,et al.  Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. , 1985, The American journal of cardiology.

[28]  L. E. Alves,et al.  THE EFFECTIVENESS OF NIFEDIPINE IN SEVERE OR UNSTABLE ANGINA PECTORIS WITH IMPAIRMENT OF LEFT VENTRICULAR FUNCTION , 1980 .

[29]  B. Singh,et al.  Use of calcium antagonists in ventricular dysfunction. , 1985, The American journal of cardiology.

[30]  B. Lorell,et al.  Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside. , 1985, Journal of the American College of Cardiology.

[31]  R. Balcon,et al.  Unpredictable response to nifedipine in severe cardiac failure. , 1980, British medical journal.

[32]  B. Lorell,et al.  Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience. , 1985, The American journal of medicine.

[33]  P. Ludbrook,et al.  Influence of nifedipine left ventricular systolic and diastolic function. Relationships to manifestations of ischemia and congestive failure. , 1981, The American journal of medicine.

[34]  W. Parmley,et al.  Pathophysiology of congestive heart failure. , 1985, The American journal of cardiology.

[35]  J. Rouleau,et al.  Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. , 1986, Circulation.

[36]  P. Reddy,et al.  Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. , 1985, The American journal of physiology.

[37]  J. Rouleau,et al.  Alterations in Left Ventricular Function and Coronary Hemodynamics with Captopril, Hydralazine and Prazosin in Chronic Ischemic Heart Failure: A Comparative Study , 1982, Circulation.

[38]  R. Towart,et al.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552). , 1980, Arzneimittel-Forschung.

[39]  H. Kreuzer,et al.  Hemodynamic effects of nisoldipine in chronic congestive heart failure. , 1983, Arzneimittel-Forschung.

[40]  T. Levine,et al.  Acute Hemodynamic Effects of Nitrendipine in Chronic Congestive Heart Failure , 1984, Journal of cardiovascular pharmacology.